September 9, 2011
Novartis has announced that the European Commission has approved Afinitor (everolimus) for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease. The approval was based on PIII data from...read more